2021 Anti-Doping Testing Figures / World Anti-Doping Agency (WADA). - Montreal : WADA, 2023

Contents:

• Executive Summary - pp. 2-9 (7 pages)
• Laboratory Report -– pp. 10-39 (30 pages)
• Sport Report - pp. 40-153 (114 pages)
• Testing Authority Report - pp. 154-267 (114 pages)
• ABP Report-Blood Analysis - pp. 268-311 (44 pages)

Report Highlights:

• A 61.2% increase in the number of samples (both urine and non-ABP blood samples) analyzed
  and reported into ADAMS: 149,758 in 2020 to 241,430 in 2021.
• An increase in the total number of samples analyzed and reported by nearly all WADAaccredited
  laboratories and WADA-approved laboratories into ADAMS in 2021 compared to 2020.
• An increase in the total number and percentage of non-ABP blood samples analyzed: 7.3%
  (10,940 of 149,758 samples) in 2020 to 9.3% (22,398 Blood + DBS samples out of 241,430).
• An increase of 36% in the number of ABP blood samples analyzed: 22,666 in 2020 to 30,821
  in 2021.
• A decrease in the total percentage of AAFs: 0.67% in 2020 (1,009 AAFs from 149,758
  samples) to 0.65% (1,560 AAFs from 241,430 samples).
• An increase in the total number of AAFs for growth hormone (GH): 1 in 2020 to 7 in 2021,
  including the first reported AAF for a GH biomarker.
• A 46% decrease in the overall number of samples analyzed: 278,047 in 2019 to 149,758 in 2020.
• A decrease in the total percentage of Adverse Analytical Findings (AAFs): 0.97% in 2019 (2,702 AAFs from 278,047 samples) to 0.67% in 2020 (1,009 AAFs from 149,758 samples).
• All WADA-accredited Laboratories saw a decrease in the total number of samples recorded.
• A decrease in the total number and percentage of non-Athlete Biological Passport (ABP) blood samples analyzed: 9.1% in 2019 (25,339 of 278,047) and 7.3% (10,940 of 149,758) in 2020.
• A decrease of 38% in the number of ABP blood samples tested: 36,401 in 2019 to 22,666 in 2020.

The World Anti-Doping Agency (WADA) has publishes its 2021 Testing Figures Report (2021 Report), which summarizes the results of all the samples WADA-accredited laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2021.

This is the first set of global testing figures under the 2021 World Anti-Doping Code (Code) that came into effect in January 2021. The 2021 Report – which includes an Executive Summary and sub-reports by Laboratory, Sport, Testing Authority and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples, blood and ABP blood data, and the resulting Adverse Analytical Findings (AAFs) and Atypical Findings (ATFs).

KADA Annual Report 2021 / Korea Anti-Doping Agency (KADA). - Seoul : KADA, 2022

Annual Report 2021-2022 / Anti-Doping Agency of Kenya (ADAK). - Nairobi : ADAK, 2022

Dopingautoriteit Annual Report 2021 (Netherlands) / Anti-doping Authority Netherlands (Dopingautoriteit). - Capelle aan den IJssel : Dopingautoriteit, 2022

Contents:

Chapter 1 – Education
Chapter 2 – Doping control
Chapter 3 – Intelligence & Investigations
Chapter 4 – Disciplinary Proceedings
Chapter 5 – Legal Affairs
Chapter 6 – Scientific research
Chapter 7 – Knowledge management
Chapter 8 – Therapeutic Use Exemptions
Chapter 9 – International Affairs
Chapter 10 – People & organisation
--------------------------
Annex 1 - Financial overview
Annex 2 - Members of Advisory Board and Committees
Annex 3 - Personnel
Annex 4 - Overview of presentations and scientific publications
Annex 5 - Secondary positions
Annex 6 – Abbreviations
Annex 7 – Result management

USADA Annual Report 2021 / United States Anti-Doping Agency (USADA). - Colorado Springs : USADA, 2022

NADA Annual Report 2021 / National Anti Doping Agency of Germany. - Bonn : Nationale Anti Doping Agentur Deutschland (NADA), 2022
NADA Material No. 100

CAS 2021/A/8284 World Anti-Doping Agency (WADA) v. World Baseball Softball Confederation (WBSC) & Laura Vigna

• Softball
• Doping (evading, refusing or failing to submit to sample collection)
• Right of a CAS panel to issue a consent award and purpose of it
• Duty of the CAS panel to verify the bona fide of the settlement agreement

1. In accordance with Article R56 para. 2, second sentence, of the CAS Code, a CAS panel is expressly allowed to issue an award embodying the terms of the settlement if all parties to the dispute agree. The CAS panel’s endorsement of the settlement agreement and incorporation in an award serves the obvious purpose of rendering it easier for the parties to enforce the settlement agreement.

2. As any settlement “may” be embodied in an award, it is up to the CAS panel to verify the bona fide of the settlement agreement, so that the consent award mechanism is not manipulated by the parties as an instrument of fraud, and to acknowledge that the settlement terms are not contrary to public policy principles or mandatory rules.

In April 2021 the International Testing Agency, on behalf of the World Baseball-Softball Confederation (WBSC), reported an anti-doping rule violation against the Italian Athlete Laura Vigna for her evasion, refusal or failure to submit to sample collection.

In July 2021 ITA and the Athlete reached an Agreement on Consequences. In this settlement the Athlete accepted a sanction of 8 months for the committing the anti-doping rule violation.

Thereupon the World Anti-Doping Agency (WADA) requested the case file to the ITA in view of a potential appeal to be filed. Hereafter in August 2021 WADA appealed against this Agreement on Consequences with the Cour of Arbitration for Sport (CAS).

WADA requested the Panel to amend the Appealed Decision and to impose on the Athlete a period of ineligibility of between 12 and 24 months.

In December 2021 WADA reported to CAS that the Parties had settled the matter. They requested that the adapted Settlement Agreement be embodied in an Arbitral Award rendered by consent of the Parties.

The Parties agree:

• The previous Agreement of July 2021 is set aside.
• The Athlete is sanctioned with a period of ineligibility of 1 year.
• The sanction starts on the date of the anti-doping rule violation, i.e on 19 November 2020.

Therefore the Court of Arbitration for Sport decides on 19 April 2022:

1. The terms of paragraph 1 of the Settlement Agreement submitted to the CAS Court Office on 2 December 2021 are hereby ratified by the CAS with the consent of the Parties and embodied in this arbitral Award.

2. The arbitral procedure with reference CAS 2021/A/8284 World Anti-Doping Agency v. World Baseball Softball Confederation (WBSC) & Laura Vigna is terminated and deleted from the CAS roll.

3. (…).

4. (…).

5. All other motions or prayers for relief are dismissed.

Jaresbericht 2021 / Natonale Anti-Doping Agentur Austria (NADA Austria). - Wien : NADA Austria, 2022

Contents:

NADA Austria

• Leitbild, Vision, Mission, Werte, Ziele, Qualitätsmanagement
• Kommissionen
• Mitarbeiterinnen und Mitarbeiter
• Nationale und internationale Kooperationen
• Central European Anti-Doping Organization (CEADO)

DopingkontrollSystem

• Dopingkontrollprogramm 2021
• Dopingkontrollstatistik 2021

Medizin

• Medikamentenabfrage - MedApp
• Medizinische Ausnahmegenehmigungen

Recht

• Zwei Jahre nach "Operation Aderlass"
• Zusammenarbeit mit den Ermittlungsbehörden / Internationale Vernetzung
• Überwachung der Einhaltung der Anti-Doping Bestimmungen
• Verstöße gegen die Anti-Doping Bestimmungen 2021

Information & Prävention

• International Standard for Education
• Online - Individuelles Lernen
• Onsite - Gemeinsames Lernen
• Schulungsprogramme
• Internationale Kooperationen

Ausblick NADA Austria
Anlagen